Hepatic Insufficiency: all 113 studies

Page 1 of 2. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic ImpairmentNot yet recruitingNCT07853040Phase 1
• Umbilical Cord Mesenchymal Stem Cell Therapy for Biliary AtresiaRecruitingNCT07797673Phase 1
• A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver DiseaseRecruitingNCT07677358Phase 1
• A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic ImpairmentRecruitingNCT07559474Phase 1
• Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic ImpairmentNot yet recruitingNCT07550634Phase 1
• A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.RecruitingNCT07401862Phase 1
• A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special PopulationsNot yet recruitingNCT07345689Phase 4
• Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive CareRecruitingNCT07343037
• Liver Diseases: Extracellular Vesicles as BiomarkersNot yet recruitingNCT07185360Not applicable
• A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver ImpairmentRecruitingNCT07165002Phase 1
• Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy SubjectsNot yet recruitingNCT07055412Phase 1
• PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic HepatitisRecruitingNCT06956482Phase 3
• A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With CirrhosisRecruitingNCT06461208Phase 3
• Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate HydrochlorideRecruitingNCT06176716Phase 1
• Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)Not yet recruitingNCT05093972Phase 1
• A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)CompletedNCT06575959Phase 1Results posted
• Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy ParticipantsCompletedNCT06190691Phase 1Results posted
• A Study of LY3502970 in Participants With Impaired and Normal Liver FunctionCompletedNCT05882032Phase 1Results posted
• A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver ProblemsCompletedNCT05731895Phase 1Results posted
• A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver ProblemsCompletedNCT05661344Phase 1Results posted
• A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver FunctionCompletedNCT05440344Phase 1Results posted
• A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic FunctionCompletedNCT04226833Phase 1Results posted
• Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its MetaboliteCompletedNCT03968848Phase 1Results posted
• A Study of Tirzepatide in Participants With Impaired Liver FunctionCompletedNCT03940742Phase 1Results posted
• Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)TerminatedNCT03295266Phase 1Results posted
• Study of Copanlisib in Hepatic or Renal ImpairmentCompletedNCT03172884Phase 1Results posted
• A Study of Abemaciclib in Participants With Varying Degrees of Liver ImpairmentCompletedNCT02387814Phase 1Results posted
• A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of PalbociclibCompletedNCT02334800Phase 1Results posted
• Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy VolunteersCompletedNCT02191865Phase 1Results posted
• A Pharmacokinetic Study of Baricitinib in Participants With Liver DiseaseCompletedNCT01870388Phase 1Results posted
• Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic EncephalopathyTerminatedNCT01846663Phase 4Results posted
• The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic EncephalopathyCompletedNCT01842581Phase 4Results posted
• A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) ImpairmentCompletedNCT01836185Phase 1Results posted
• The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)CompletedNCT01797536Phase 1Results posted
• A Single Dose Study of LY2605541 in Participants With Liver ImpairmentCompletedNCT01751399Phase 1Results posted
• Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)CompletedNCT01512693Phase 1Results posted
• A Study of LY2140023 in Hepatically-Impaired ParticipantsCompletedNCT01475136Phase 1Results posted
• Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver FunctionCompletedNCT01111318Phase 1Results posted
• Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)CompletedNCT01043926Phase 1Results posted
• Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic ImpairmentCompletedNCT00859053Phase 1Results posted
• Evaluation Of Hepatic Impairment On AG-013736 PharmacokineticsCompletedNCT00692341Phase 1Results posted
• A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic FunctionCompletedNCT07625618Phase 1
• A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral DoseCompletedNCT07102095Phase 1
• A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)CompletedNCT07049939Phase 1
• A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.CompletedNCT07037394Phase 4
• A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver ProblemsCompletedNCT06957756Phase 1
• A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic FunctionCompletedNCT06858696Phase 1
• A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy ParticipantsCompletedNCT06719128Phase 1
• Clinical Trial of FCN-437c Capsule in Patients With Hepatic InsufficiencyCompletedNCT06620731Phase 1
• A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic FunctionCompletedNCT06390410Phase 1
• Balloon-occluded Retrograde Transvenous Obliteration for Gastric Variceal RebleedingStatus unknownNCT06106971Phase 3
• A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionCompletedNCT05916560Phase 1
• A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid MalignanciesTerminatedNCT05209295Phase 1
• Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic FunctionCompletedNCT04993404Phase 1
• A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196CompletedNCT04867941Phase 1
• TReatment for ImmUne Mediated PathopHysiologyActive, not recruitingNCT04862221Phase 2
• Assessment of Remnant Liver Function in ALPPS by Gd-EOB-DTPA Enhanced MRIStatus unknownNCT04559451
• Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain DiseasesCompletedNCT04170309
• Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic InsufficiencyCompletedNCT04147936Not applicable
• Pharmacogenetics Sampling of the CC-90007-CP-003 Study CohortCompletedNCT04097704
• Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic FunctionCompletedNCT03962049Phase 1
• A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver ProblemsCompletedNCT03842761Phase 1
• Liver Function After Intravenous Methylprednisolone AdministrationCompletedNCT03667157Phase 4
• An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver FunctionCompletedNCT03515980Phase 1
• Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver FunctionCompletedNCT03465059Phase 1
• Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its MetabolitesCompletedNCT03376841Phase 1
• A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy ParticipantsCompletedNCT03341884Phase 1
• Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)CompletedNCT03306667Phase 1
• TONKA Versus Legalon for Lowering Hepatic Enzymes in Liver Function Disorder Patients.Status unknownNCT03216668Phase 3
• Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)CompletedNCT02894385Phase 1
• Major Liver Resection: Early Clotting Disorders and Functional Impairment.CompletedNCT02813538
• Prognostic Impact of Organ Damage in STEMI PatientsCompletedNCT02800421
• Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure HepatectomiesCompletedNCT02753517Not applicable
• Mitochondrial Function in Patients With Severe Liver DiseaseTerminatedNCT02457702Not applicable
• Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy VolunteersCompletedNCT02265627Phase 1
• Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic ImpairmentCompletedNCT02259855Phase 1
• Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic InsufficiencyCompletedNCT02249442Phase 1
• Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of NevirapineCompletedNCT02184091Phase 1
• Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy SubjectsCompletedNCT02183376Phase 1
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionCompletedNCT02170571Phase 1
• A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver FunctionCompletedNCT02161224Phase 1
• Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic ImpairmentCompletedNCT02120547Phase 1
• Extracorporeal Photopheresis After Liver TransplantCompletedNCT02090621Phase 2
• Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)WithdrawnNCT01923376Not applicable
• Metabolomics of Liver Regeneration Following Partial Hepatectomy in Healthy Living Liver DonorsCompletedNCT01922323
• Single Dose of 9-cis-retinoic Acid in Hepatic PatientsCompletedNCT01891526
• Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy SubjectsCompletedNCT01860326Phase 1
• Quantification of Drugs and Their Degradation ProductsStatus unknownNCT01828372Not applicable
• Hepatocyte Matrix Implant Study IndonesiaStatus unknownNCT01335568Phase 1
• A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic DysfunctionCompletedNCT01273493Phase 1
• Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic DiseaseCompletedNCT01261923Phase 1/2
• A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) FunctionCompletedNCT01186588Phase 1
• Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)CompletedNCT01114490Phase 1
• Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care UnitsTerminatedNCT01079104Not applicable
• Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care UnitsTerminatedNCT01079091Not applicable
• Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)CompletedNCT01043887Phase 1
• Raltegravir in Patients With End Stage Liver Disease and in Transplant RecipientsCompletedNCT01022476Phase 1/2
• Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032CompletedNCT01019070Phase 1
• A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic FunctionCompletedNCT00969813Phase 1
• Pharmacokinetics of Everolimus in Subjects With Hepatic InsufficiencyCompletedNCT00968591Phase 1

← Hepatic Insufficiency overview